Fluvoxamine modulates pain sensation and affective processing of pain in human brain.
To better understand the antinociceptive effect of fluvoxamine, we measured regional cerebral blood flow during laser-evoked pain and hot sensations using H(2)15O positron emission tomography and also subjective pain and hot sensations before and after fluvoxamine or placebo administration for 7 days to 12 healthy volunteers. The subjectively rated pain score was significantly reduced by fluvoxamine administration. Painful stimuli activated multiple brain regions. After fluvoxamine administration the ipsilateral anterior cingulate cortex (ACC), contralateral insular cortex (IC), and contralateral secondary somatosensory cortex (SII) activations were reduced. The bilateral IC activation was also reduced in the placebo group. These results suggest that fluvoxamine specifically reduced activation of the ACC and SII, which are areas concerned with the affective and integrative components of pain.
Nemoto
Hidenori
H
Department of Neurology and Clinical Research, Gunma University School of Medicine, Maebashi, Japan.
Toda
Hikaru
H
Nakajima
Takashi
T
Hosokawa
Shin
S
Okada
Yuko
Y
Yamamoto
Koujirou
K
Horiuchi
Ryuya
R
Endo
Keigo
K
Ida
Itsuro
I
Mikuni
Masahiko
M
Goto
Fumio
F
D000328:Adult; D000339:Affect / Q000187:drug effects*; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000503:physiopathology*; D001931:Brain Mapping; D002560:Cerebrovascular Circulation / Q000187:drug effects; D005260:Female; D016666:Fluvoxamine / Q000008:administration & dosage / Q000494:pharmacology*; D006358:Hot Temperature; D006801:Humans; D007834:Lasers; D008297:Male; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology* / Q000523:psychology; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D016037:Single-Blind Method; D014055:Tomography, Emission-Computed
D014151:Anti-Anxiety Agents; D016666:Fluvoxamine; D017367:Selective Serotonin Reuptake Inhibitors